Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016, Article ID 5246217, 9 pages
http://dx.doi.org/10.1155/2016/5246217
Review Article

Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers

Department of Biological & Biomedical Sciences, Aga Khan University, P.O. Box 74800, Karachi, Pakistan

Received 14 October 2015; Accepted 6 January 2016

Academic Editor: Stamatios Theocharis

Copyright © 2016 Zehra Jamil et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Lindhardt Johansen, C. P. Hagen, T. H. Johannsen et al., “Anti-mullerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development,” International Journal of Endocrinology, vol. 2013, Article ID 198698, 10 pages, 2013. View at Publisher · View at Google Scholar
  2. A. Karkanaki, C. Vosnakis, and D. Panidis, “The clinical significance of anti-müllerian hormone evaluation in gynecological endocrinology,” Hormones, vol. 10, no. 2, pp. 95–103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Dewailly, C. Y. Andersen, A. Balen et al., “The physiology and clinical utility of anti-Müllerian hormone in women,” Human Reproduction Update, vol. 20, no. 3, Article ID dmt062, pp. 370–385, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. E. W. Freeman, M. D. Sammel, H. Lin, and C. R. Gracia, “Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 5, pp. 1673–1680, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. T. W. Kelsey, P. Wright, S. M. Nelson, R. A. Anderson, and W. H. B. Wallace, “A validated model of serum Anti-Müllerian hormone from conception to menopause,” PLoS ONE, vol. 6, no. 7, Article ID e22024, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. S. L. Broer, M. J. C. Eijkemans, G. J. Scheffer et al., “Anti-Müllerian hormone predicts menopause: a long-term follow-up study in normoovulatory women,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 8, pp. 2532–2539, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Rice, K. Ojha, S. Whitehead, and H. Mason, “Stage-specific expression of androgen receptor, follicle-stimulating hormone receptor, and anti-Müllerian hormone type II receptor in single, isolated, human preantral follicles: Relevance to polycystic ovaries,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 3, pp. 1034–1040, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Watanabe, T. R. Clarke, A. H. Lane, X. Wang, and P. K. Donahoe, “Endogenous expression of Mullerian inhibiting substance in early postnatal rat Sertoli cells requires multiple steroidogenic factor-1 and GATA-4-binding sites,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 4, pp. 1624–1629, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. I. Demeestere, F. Moffa, F. Peccatori, C. Poirot, and E. Shalom-Paz, “Multiple approaches for individualized fertility protective therapy in cancer patients,” Obstetrics and Gynecology International, vol. 2012, Article ID 961232, 12 pages, 2012. View at Publisher · View at Google Scholar
  10. P. Bhattacharya and A. F. Keating, “Ovarian metabolism of xenobiotics,” Experimental Biology and Medicine, vol. 236, no. 7, pp. 765–771, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S. L. Broer, B. Mol, M. Dólleman, B. C. Fauser, and F. J. M. Broekmans, “The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome,” Current Opinion in Obstetrics and Gynecology, vol. 22, no. 3, pp. 193–201, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. V. Jeppesen, R. A. Anderson, T. W. Kelsey et al., “Which follicles make the most anti-Müllerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection,” Molecular Human Reproduction, vol. 19, no. 8, pp. 519–527, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. I. B. Carlsson, J. E. Scott, J. A. Visser, O. Ritvos, A. P. N. Themmen, and O. Hovatta, “Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro,” Human Reproduction, vol. 21, no. 9, pp. 2223–2227, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. A. L. L. Durlinger, M. J. G. Gruijters, P. Kramer et al., “Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary,” Endocrinology, vol. 143, no. 3, pp. 1076–1084, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Kalich-Philosoph, H. Roness1, A. Carmely et al., “Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility,” Science Translational Medicine, vol. 5, no. 185, Article ID 185ra62, 2013. View at Publisher · View at Google Scholar
  16. J. van Disseldorp, C. B. Lambalk, J. Kwee et al., “Comparison of inter-and intra-cycle variability of anti-Müllerian hormone and antral follicle counts,” Human Reproduction, vol. 25, no. 1, pp. 221–227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. J. F. Randolph, S. D. Harlow, M. E. Helmuth, H. Zheng, and D. S. McConnell, “Updated assays for inhibin B and AMH provide evidence for regular episodic secretion of inhibin B but not AMH in the follicular phase of the normal menstrual cycle,” Human Reproduction, vol. 29, no. 3, Article ID det447, pp. 592–600, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Tal and D. B. Seifer, “Potential mechanisms for racial and ethnic differences in antimüllerian hormone and ovarian reserve,” International Journal of Endocrinology, vol. 2013, Article ID 818912, 7 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Lie Fong, J. A. Visser, C. K. Welt et al., “Serum anti-müllerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 12, pp. 4650–4655, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. I. A. J. van Rooij, F. J. M. Broekmans, G. J. Scheffer et al., “Serum antimüllerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study,” Fertility and Sterility, vol. 83, no. 4, pp. 979–987, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. S. L. Broer, F. J. M. Broekmans, J. S. E. Laven, and B. C. J. M. Fauser, “Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications,” Human Reproduction Update, vol. 20, no. 5, pp. 688–701, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. H. G. Burger, E. C. Dudley, D. M. Robertson, and L. Dennerstein, “Hormonal changes in the menopause transition,” Recent Progress in Hormone Research, vol. 57, pp. 257–275, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Perloe, D. P. Levy, and E. S. Sills, “Strategies for ascertaining ovarian reserve among women suspected of subfertility,” International Journal of Fertility and Women's Medicine, vol. 45, no. 3, pp. 215–224, 2000. View at Google Scholar · View at Scopus
  24. A. Bukman and M. J. Heineman, “Ovarian reserve testing and the use of prognostic models in patients with subfertility,” Human Reproduction Update, vol. 7, no. 6, pp. 581–590, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. S. A. Willis, T. J. Kuehl, A. M. Spiekerman, and P. J. Sulak, “Greater inhibition of the pituitary–ovarian axis in oral contraceptive regimens with a shortened hormone-free interval,” Contraception, vol. 74, no. 2, pp. 100–103, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. C. H. Gravholt, “Clinical practice in Turner syndrome,” Nature Reviews Endocrinology, vol. 1, no. 1, pp. 41–52, 2005. View at Publisher · View at Google Scholar
  27. S. Franks, H. Mason, and D. Willis, “Follicular dynamics in the polycystic ovary syndrome,” Molecular and Cellular Endocrinology, vol. 163, no. 1-2, pp. 49–52, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Colao, C. di Somma, R. Pivonello, A. Faggiano, G. Lombardi, and S. Savastano, “Medical therapy for clinically non-functioning pituitary adenomas,” Endocrine-Related Cancer, vol. 15, no. 4, pp. 905–915, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. S. M. Nelson, “Biomarkers of ovarian response: current and future applications,” Fertility and Sterility, vol. 99, no. 4, pp. 963–969, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. V. Smith, T. Osianlis, and B. Vollenhoven, “A review of luteinizing hormone and its role in ovarian reserve testing,” International Journal of Reproduction, Contraception, Obstetrics and Gynecology, vol. 3, no. 1, pp. 11–18, 2014. View at Publisher · View at Google Scholar
  31. A. Weghofer, S. Schnepf, D. Barad, and N. Gleicher, “The impact of luteinizing hormone in assisted reproduction: a review,” Current Opinion in Obstetrics and Gynecology, vol. 19, no. 3, pp. 253–257, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. I. Noci, R. Biagiotti, M. Maggi, F. Ricci, A. Cinotti, and G. Scarselli, “Low day 3 luteinizing hormone values are predictive of reduced response to ovarian stimulation,” Human Reproduction, vol. 13, no. 3, pp. 531–534, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Chun, “Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome,” Clinical and Experimental Reproductive Medicine, vol. 41, no. 2, pp. 86–91, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Iliodromiti, T. W. Kelsey, O. Wu, R. A. Anderson, and S. M. Nelson, “The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature,” Human Reproduction Update, vol. 20, no. 4, pp. 560–570, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. C. K. Welt, “Regulation and function of inhibins in the normal menstrual cycle,” Seminars in Reproductive Medicine, vol. 22, no. 3, pp. 187–193, 2004. View at Google Scholar
  36. S. Muttukrishna, H. Suharjono, H. McGarrigle, and M. Sathanandan, “Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients?” BJOG, vol. 111, no. 11, pp. 1248–1253, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. M. R. Sowers, A. D. Eyvazzadeh, D. McConnell et al., “Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition,” Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 9, pp. 3478–3483, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Makanji, J. Zhu, R. Mishra et al., “Inhibin at 90: from discovery to clinical application, a historical review,” Endocrine Reviews, vol. 35, no. 5, pp. 747–794, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Krawczuk-Rybak, E. Leszczynska, M. Poznanska, B. Zelazowska-Rutkowska, and J. Wysocka, “Anti-Müllerian hormone as a sensitive marker of ovarian function in young cancer survivors,” International Journal of Endocrinology, vol. 2013, Article ID 125080, 6 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. K. J. Ryan, “Biochemistry of aromatase: significance to female reproductive physiology,” Cancer Research, vol. 42, no. 8, supplement, pp. 3342s–3344s, 1982. View at Google Scholar · View at Scopus
  41. V. Mais, N. S. Cetel, K. N. Muse, M. E. Quigley, R. L. Reid, and S. S. Yen, “Hormonal dynamics during luteal-follicular transition,” The Journal of Clinical Endocrinology & Metabolism, vol. 64, no. 6, pp. 1109–1114, 1987. View at Publisher · View at Google Scholar · View at Scopus
  42. J. L. Frattarelli, D. F. Lauria-Costab, B. T. Miller, P. A. Bergh, and R. T. Scott Jr., “Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles,” Fertility and Sterility, vol. 74, no. 3, pp. 512–517, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. T.-H. Lee, C.-H. Liu, C.-C. Huang et al., “Serum anti-müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles,” Human Reproduction, vol. 23, no. 1, pp. 160–167, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. A. La Marca, G. Stabile, A. Carducci Artenisio, and A. Volpe, “Serum anti-Mullerian hormone throughout the human menstrual cycle,” Human Reproduction, vol. 21, no. 12, pp. 3103–3107, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. S. M. Nelson, R. A. Anderson, F. J. Broekmans, N. Raine-Fenning, R. Fleming, and A. La Marca, “Anti-Müllerian hormone: clairvoyance or crystal clear?” Human Reproduction, vol. 27, no. 3, pp. 631–636, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. F. J. M. Broekmans, D. De Ziegler, C. M. Howles, A. Gougeon, G. Trew, and F. Olivennes, “The antral follicle count: practical recommendations for better standardization,” Fertility and Sterility, vol. 94, no. 3, pp. 1044–1051, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. A. La Marca, S. Giulini, A. Tirelli et al., “Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology,” Human Reproduction, vol. 22, no. 3, pp. 766–771, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. S. M. Nelson, R. W. Yates, H. Lyall et al., “Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception,” Human Reproduction, vol. 24, no. 4, pp. 867–875, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Josso, R. Rey, and J.-Y. Picard, “Testicular anti-müllerian hormone: clinical applications in DSD,” Seminars in Reproductive Medicine, vol. 30, no. 5, pp. 364–373, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Aksglaede, P. Christiansen, K. Sørensen et al., “Serum concentrations of Anti-Müllerian Hormone (AMH) in 95 patients with Klinefelter syndrome with or without cryptorchidism,” Acta Paediatrica, International Journal of Paediatrics, vol. 100, no. 6, pp. 839–845, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. M. M. Lee, M. Misra, P. K. Donahoe, and D. T. MacLaughlin, “MIS/AMH in the assessment of cryptorchidism and intersex conditions,” Molecular and Cellular Endocrinology, vol. 211, no. 1-2, pp. 91–98, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. J. A. Visser, A. C. S. Hokken-Koelega, G. R. J. Zandwijken, A. Limacher, M. B. Ranke, and C. E. Flück, “Anti-Müllerian hormone levels in girls and adolescents with Turner syndrome are related to karyotype, pubertal development and growth hormone treatment,” Human Reproduction, vol. 28, no. 7, pp. 1899–1907, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Sahmay, T. Usta, C. T. Erel et al., “Is there any correlation between amh and obesity in premenopausal women?” Archives of Gynecology and Obstetrics, vol. 286, no. 3, pp. 661–665, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. D. Rachoń and H. Teede, “Ovarian function and obesity—interrelationship, impact on women's reproductive lifespan and treatment options,” Molecular and Cellular Endocrinology, vol. 316, no. 2, pp. 172–179, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Metwally, W. L. Ledger, and T. C. Li, “Reproductive endocrinology and clinical aspects of obesity in women,” Annals of the New York Academy of Sciences, vol. 1127, pp. 140–146, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. K. P. Tremellen, M. Kolo, A. Gilmore, and D. N. Lekamge, “Anti-müllerian hormone as a marker of ovarian reserve,” Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 45, no. 1, pp. 20–24, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. A. P. Yates, O. Rustamov, S. A. Roberts et al., “Anti-Müllerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF,” Human Reproduction, vol. 26, no. 9, pp. 2353–2362, 2011. View at Publisher · View at Google Scholar
  58. Y. Tokura, O. Yoshino, S. Ogura-Nose et al., “The significance of serum anti-Müllerian hormone (AMH) levels in patients over age 40 in first IVF treatment,” Journal of Assisted Reproduction and Genetics, vol. 30, no. 6, pp. 821–825, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. R. J. Norman, D. Dewailly, R. S. Legro, and T. E. Hickey, “Polycystic ovary syndrome,” The Lancet, vol. 370, no. 9588, pp. 685–697, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. M. P. Lauritsen, J. G. Bentzen, A. Pinborg et al., “The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Müllerian hormone,” Human Reproduction, vol. 29, no. 4, pp. 791–801, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Bungum, F. Franssohn, M. Bungum, P. Humaidan, and A. Giwercman, “The circadian variation in Anti-Müllerian hormone in patients with polycystic ovary syndrome differs significantly from normally ovulating women,” PLoS ONE, vol. 8, no. 9, Article ID e68223, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. T. B. Eilertsen, E. Vanky, and S. M. Carlsen, “Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?” Human Reproduction, vol. 27, no. 8, pp. 2494–2502, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Rosendahl, C. Y. Andersen, N. la Cour Freiesleben, A. Juul, K. Løssl, and A. N. Andersen, “Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age,” Fertility and Sterility, vol. 94, no. 1, pp. 156–166, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. R. A. Rey, C. Lhomme, I. Marcillac et al., “Antimüllerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum α-inhibin and estradiol,” American Journal of Obstetrics & Gynecology, vol. 174, no. 3, pp. 958–965, 1996. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Teixeira, S. Maheswaran, and P. K. Donahoe, “Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications,” Endocrine Reviews, vol. 22, no. 5, pp. 657–674, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. R. Fleming, F. Broekmans, C. Calhaz-Jorge et al., “Can anti-Müllerian hormone concentrations be used to determine gonadotrophin dose and treatment protocol for ovarian stimulation?” Reproductive BioMedicine Online, vol. 26, no. 5, pp. 431–439, 2013. View at Publisher · View at Google Scholar · View at Scopus